Schedule 13G ownership disclosure
Viridian Therapeutics Inc
Common Stock, $0.01 par value · CUSIP: 92790C104
Event date: 2025-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Kynam Capital Management, LP
Shares: 1,470,541 · Class: 1.54%
- Kynam Capital Management GP, LLC
Shares: 1,470,541 · Class: 1.54%
- Yue Tang
Shares: 1,470,541 · Class: 1.54%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001907884-26-000004
- Form type
- SCHEDULE 13G/A
- Filer
- Kynam Capital Management, LP
- CIK
- CIK 1907884
- Filed
- Feb 17, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership